18th May 2016 06:23
LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Wednesday said the top-line results from the trial on its Lynparza drug in combination with paclitaxel chemotherapy did not meet the primary endpoint target for overall survival.
The endpoint was not met on trials of the combination in advanced gastric cancer patients, AstraZeneca said. While there was a numerical survival trend in the Lynparza-paclitaxel combination, it did not meet statistical significance.
"While there was a numerical trend for survival benefit with Lynparza plus paclitaxel in the GOLD trial, we are disappointed that this did not reach statistical significance," said Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca